Tradestie Institutional Equity Comparison Engine

ANNX vs NRIX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

NRIX Overall Edge

NRIX Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Nurix Therapeutics, Inc. Common stock (NRIX) driven by superior Valuation, Growth & Margin, Options & Structure while ANNX counters with relative strength in Momentum & Technical. Fundamentally, ANNX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus NRIX at N/M Forward P/E and 41.3% operating margin (+8426.3% YoY). In options structure, ANNX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro) against NRIX sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner NRIX
ANNX N/M vs NRIX N/M Fwd P/E
Growth & Margin Winner NRIX
Op Margin 0.0% vs 41.3% ยท YoY +0.0% vs +8426.3%
Momentum & Technical Winner ANNX
1Y +28.6% vs +11.2% ยท 52W Pos 18% vs 13%
Options & Structure Winner NRIX
BREAKDOWN (100th %ile IV) vs BREAKDOWN (4th %ile IV)
ANNX NASDAQ
Annexon, Inc. Common Stock
Pharmaceutical Preparations
$3.48
-2.38% 1D
Market Cap $747.8M
1M Return -13.09%
1Y Return +28.6%
Forward P/E N/M
Unified AI Score
43.5 / 100 HOLD
Tech 37.0 Fund 55.0 Flow 72.0 Mom 60.0
NRIX NASDAQ
Nurix Therapeutics, Inc. Common stock
Pharmaceutical Preparations
$14.24
-3.33% 1D
Market Cap $1.7B
1M Return -42.88%
1Y Return +11.25%
Forward P/E N/M
Unified AI Score
50.1 / 100 HOLD
Tech 45.0 Fund 54.0 Flow 64.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ANNX +28.6% NRIX +11.25% Spread: +17.35 pp (ANNX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ANNX TTM Op. Margin: 0.0% NRIX TTM Op. Margin: 41.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANNX vs NRIX. Trailing 12-month operating profitability (ANNX 0.0% vs NRIX 41.3%) and valuation multiples (ANNX N/M vs NRIX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ANNX (2) vs NRIX (7)
Institutional Metric ANNX NRIX Criterion Row Winner
Market Capitalization Scale $747.8M $1.7B Larger Scale NRIX
Trailing P/E Ratio Valuation N/M 6.4x Lower Multiple NRIX
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +8426.3% Higher Growth NRIX
Operating Margin (TTM) Profitability 0.0% 41.3% Higher Margin NRIX
Net Profit Margin Profitability 0.0% 42.0% Higher Margin NRIX
Return on Equity (ROE) Capital Efficiency -130.8% 44.0% Higher ROE NRIX
52-Week Range Position Momentum 18% ($3โ€“$7) 13% ($12โ€“$28) Stronger Trend ANNX
Beta / 30D Volatility Risk Regime 1.69ฮฒ ยท 63% Vol 0.98ฮฒ ยท 138% Vol Lower Realized Risk ANNX
Unified Institutional Score Composite Signal 43.5 / 100 (HOLD) 50.1 / 100 (HOLD) Higher Composite NRIX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ANNX vs NRIX Buy Guide
ANNX BREAKDOWN
88d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live ANNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
NRIX BREAKDOWN
63d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live NRIX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ANNX nor NRIX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.